Lonigutamab is a humanized IgG1κ monoclonal antibody that targets the insulin-like growth factor 1 receptor (IGF-1R), a protein involved in tumor growth and survival.
Key Features:
- Target: Specifically binds to IGF-1R, expressed on various tumor cells.
- Mechanism: Help to develop antibody-drug conjugates (ADCs) that deliver cytotoxic agents directly to IGF-1R-expressing tumor cells.
- Therapeutic Use: Investigated for treating cancers such as breast cancer, ovarian cancer, and non-small cell lung cancer.
Applications:
- Cancer Research: To develop ADCs targeting IGF-1R-expressing tumors, improving treatment specificity while reducing systemic toxicity.
- ADC Development: To create ADCs like W0101, which have shown promise in preclinical studies.
Handling and Storage:
- Storage: Store at -20°C, protected from light.
- Precautions: Use personal protective equipment and ensure proper ventilation during handling.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
